Lim, E. A., Bendell, J. C., Falchook, G. S., Bauer, T. M., Drake, C. G., Choe, J. H., George, D. J., Karlix, J. L., Ulahannan, S., Sachsenmeier, K. F., Russell, D. L., Moorthy, G., Sidders, B. S., Pilling, E. A., Chen, H., Hattersley, M. M., Das, M., Kumar, R., Pouliot, G. P., & Patel, M. R. (2022). Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. Clinical Cancer Research, 28(22), 4871–4884. https://doi.org/10.1158/1078-0432.ccr-22-0612